Hassan_2019_Biomed.Pharmacother_109_2513

Reference

Title : The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches - Hassan_2019_Biomed.Pharmacother_109_2513
Author(s) : Hassan M , Raza H , Abbasi MA , Moustafa AA , Seo SY
Ref : Biomed Pharmacother , 109 :2513 , 2019
Abstract :

Novel drug development is onerous, time consuming and overpriced process with particularly low success and relatively high enfeebling rates. To overcome this burden, drug repositioning approach is being used to predict the possible therapeutic effects of FDA approved drugs in different diseases. Herein, we designed a computational and enzyme inhibitory mechanistic approach to fetch the promising drugs from the pool of FDA approved drugs against AD. The binding interaction patterns and conformations of screened drugs within active region of AChE were confirmed through molecular docking profiles. The possible associations of selected drugs with AD genes were predicted by pharmacogenomics analysis and confirmed through data mining. The stability behaviour of docked complexes (Drugs-AChE) were checked by MD simulations. The possible therapeutic potential of repositioned drugs against AChE were checked by in vitro analysis. Taken together, Cinitapride displayed a comparable results with standard and can be used as possible therapeutic agent in the treatment of AD.

PubMedSearch : Hassan_2019_Biomed.Pharmacother_109_2513
PubMedID: 30551512

Related information

Citations formats

Hassan M, Raza H, Abbasi MA, Moustafa AA, Seo SY (2019)
The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches
Biomed Pharmacother 109 :2513

Hassan M, Raza H, Abbasi MA, Moustafa AA, Seo SY (2019)
Biomed Pharmacother 109 :2513